Integer Holdings Co. (NYSE:ITGR) Shares Sold by Trust Point Inc.

Trust Point Inc. trimmed its position in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 18.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,533 shares of the medical equipment provider's stock after selling 2,309 shares during the quarter. Trust Point Inc.'s holdings in Integer were worth $1,396,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. boosted its holdings in Integer by 4.4% in the fourth quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider's stock valued at $220,000 after purchasing an additional 71 shares during the period. Contravisory Investment Management Inc. boosted its stake in shares of Integer by 55.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 80 shares during the period. HighTower Advisors LLC grew its position in shares of Integer by 0.8% during the third quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider's stock worth $1,579,000 after buying an additional 90 shares in the last quarter. Azzad Asset Management Inc. ADV grew its position in shares of Integer by 0.9% during the third quarter. Azzad Asset Management Inc. ADV now owns 11,572 shares of the medical equipment provider's stock worth $1,504,000 after buying an additional 107 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in shares of Integer by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,800 shares of the medical equipment provider's stock worth $769,000 after buying an additional 145 shares during the period. 99.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ITGR has been the subject of several analyst reports. Citigroup boosted their price target on shares of Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a report on Wednesday, December 11th. Piper Sandler reiterated an "overweight" rating and set a $140.00 target price (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. Truist Financial increased their target price on Integer from $147.00 to $163.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Benchmark lifted their price target on Integer from $130.00 to $140.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Integer currently has a consensus rating of "Moderate Buy" and a consensus target price of $146.56.

Integer Stock Performance

Shares of Integer stock traded down $0.54 on Friday, reaching $140.37. 155,579 shares of the stock were exchanged, compared to its average volume of 208,699. Integer Holdings Co. has a 1-year low of $94.56 and a 1-year high of $146.36. The business has a fifty day moving average price of $137.94 and a two-hundred day moving average price of $130.95. The firm has a market capitalization of $4.71 billion, a PE ratio of 43.32, a PEG ratio of 1.81 and a beta of 1.13. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.